Navigation Links
Studies Investigate New Methodologies to Improve Recovery and Survival Strategies for Patients Undergoing Hematopoietic Cell Transplantation
Date:12/10/2011

demonstrated recently by using a less aggressive, non-myeloablative preparative regimen, followed by an infusion of unmanipulated bone marrow and the post-transplant use of a common chemotherapy drug, cyclophosphamide (Cy), but relapse is relatively common, especially in those with high-risk myeloid malignancies. This study sought to determine whether it is possible to decrease the probability of relapse in these high-risk patients by using a myeloablative preparative regimen with PBSCs, instead of bone marrow, as the graft source.

Between January 2009 and March 2011, the investigators initiated a clinical trial enrolling 20 patients with high-risk blood cancers, including leukemia and both Hodgkin and non-Hodgkin lymphoma, undergoing haploidentical HCT. Participants were eligible for the trial if they were perceived to be at a high risk of relapse using a less aggressive preparative regimen following transplantation. Eleven patients (55%) had relapsed or refractory disease, while the remaining nine patients (45%) had standard-risk disease, the majority being leukemia patients in remission but associated with poor-risk features. After the administration of the myeloablative preparative regimen, patients underwent transplantation with PBSCs, followed by an immunosuppressive regimen of Cy (50mg/kg/day) on days three and four post transplant along with other supportive therapies.

After an average follow-up of 14 months, investigators reported an estimated one-year overall survival rate of 74 percent and a disease-free survival (DFS) rate of 51 percent for all patients; for standard risk patients, one year overall survival was 100 percent and DFS was 76 percent. Non-relapse mortality at 100 days and 12 months was 10 percent for all patients and zero for standard risk patients. The cumulative incidence of chronic GVHD at one year was 42 percent.

Non-infectious fever developed in 90 percent of patients within a median of 2.5 days of transplant and w
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Bayers Drospirenone-containing Combination Oral Contraceptives: FDA Advisory Committees Affirm Positive Benefit-risk Profile and Recommend an Update of Labels to Reflect Information From Available Studies
2. Genomic Health Announces Presentation of Sixteen Oncotype DX Studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
3. Montage Announces Three More Hospitals Implement Their On-Demand Search and Data Mining Technology for Radiology Studies
4. Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
5. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
6. Data From Phase 2 Clinical Studies of Telotristat Etiprate in Patients With Carcinoid Syndrome to be Presented at North American Neuroendocrine Tumor Society Meeting
7. New Clinical Studies Presented at the American Society of Anesthesiologists Annual Meeting Show Benefits of Masimo Noninvasive Technologies: SpHb, PVI, RRa, and SEDLine
8. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
9. Managing Bioequivalence Studies to Optimize the Quality, Cost, and Speed of Generics Manufacturing
10. FDA Seeks Comment on Proposed Guidelines for High-Quality Clinical Studies
11. Urgent® PC Clinical Studies Results Scheduled for Presentation at International Continence Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
(Date:10/31/2014)...  Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is ... in combination with gemcitabine, will be reimbursed via the ... cancer from 1 November. In ... th most common cause of cancer mortality. Pancreatic ... the lowest 5-year survival of all common cancers at ...
(Date:10/31/2014)... 31, 2014 Today, Analysts Review ... CELG ), Bristol-Myers Squibb Co. (NYSE: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,Celgene Corporation Research Reports ,On October 23, 2014, Celgene ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
... Jan. 27, 2011 Significant flooding occurred in many ... January 2011.  Thousands of residents were affected.  A disaster ... on 29 December 2010, by Premier of Queensland, Anna ... in to help their fellow citizens clean-up in the ...
... China and ROCKVILLE, Md., Jan. 26, 2011 /PRNewswire-Asia/ -- Synutra ... formula company in China and a producer, marketer and seller ... that it plans to release its financial results for the ... 2011 after market close. The Company will ...
Cached Medicine Technology:DSM Joins International Response to Flooding in Australia 2DSM Joins International Response to Flooding in Australia 3Synutra to Announce Third Quarter Fiscal 2011 Financial Results 2
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss review that ... loss program ever developed. It promises to provide users the ... no wonder after all that this has become the most ... and workout fat loss program was created by Joel Marion, ... the author of this fat loss system, the method can ...
(Date:10/31/2014)... Lake City, UT (PRWEB) October 31, 2014 ... announce the new Activz Silver line offering ... and cleansing wipes. For over a century, silver has ... formula found in Activz Silver products is the most ... U.S. patents, has a unique chemical structure that supports ...
(Date:10/31/2014)... In terms of duration of treatment and cost, ... from accelerated partial breast irradiation (APBI) with proton ... new research from The University of Texas MD ... a cost analysis study based on typical patient ... allowable charges for eight different types of partial ...
(Date:10/31/2014)... Colorado (PRWEB) October 31, 2014 The ... that this workout program was developed by Dan Long, ... become well-known as a fitness professional and life coach. ... fat and having toned muscles is not impossible , ... based on suspension training. Suspension training promises efficiency when ...
(Date:10/31/2014)... NY (PRWEB) October 31, 2014 ... the most remarkable gifts of life — building a ... matching extraordinary surrogate mothers and donors with hopeful intended ... in unforeseen circumstances. , It’s a collective aptitude of ... agencies, surrogacy lawyers, and fertility clinics that help provide ...
Breaking Medicine News(10 mins):Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3
... the prosthesis that has helped thousands of disabled worldwide to ... first centre on foreign soil . ,The Colombian government ... of the artificial limb, to set up base in the ... with a Colombia-based NGO. ,M.K. Mathur of BMVSS ...
... disease (STD) has surpassed Neisseria gonorrhea in prevalence among young ... a big menace, researchers say . ,The new ... the 1980s. It can cause inflammation of the urethra (the ... the cervix and the lining of the uterus in women, ...
... on less than 50 pence (Rs.40) a day will benefit from ... the number of children who die before their fifth birthday. ... when mothers give birth, a doctor or nurse is available to ... much better chance of survival. ,Groups at a high ...
... are weak at mathematics, reading, and writing better watch out ... research suggests that such symptoms may cause students to ... Bachmann of Chappaqua Public Schools in New York, the study ... graders, who completed Sleep Disorders Inventory for Students - Child ...
... new genetic cause for Joubert syndrome (JS), an inherited ... brainstem-the structures in the brain that coordinate movements and ... and consciousness. ,This is the fifth gene ... syndrome. Researchers at Seattle Children's Hospital Research Institute, the ...
... University of Washington and other members of an international ... genome functions . While previous studies of the human ... insight into the non-gene sequences making up the vast ... non-gene sequences are so-called "regulatory elements" that contain instructions ...
Cached Medicine News:Health News:Jaipur Foot All Set to Launch Its Centre in Columbia 2Health News:British Funds 250 Million Pounds to Reduce Child Mortality 2Health News:Students With Sleep Disorder Symptoms Score Badly in Maths 2Health News:Boffins Identify Fifth Gene Behind Joubert Syndrome 2Health News:Researchers Cracking the Human Genome Function 2Health News:Researchers Cracking the Human Genome Function 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 12 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 11 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 9 mm....
Medicine Products: